Literature DB >> 1392004

Immunization against dental caries.

M W Russell1.   

Abstract

The development of a vaccine against dental caries involves identification of appropriate antigens of mutans streptococci against which protective immune responses can be mounted, and the selection of a method of immunization that will generate sustained levels of salivary antibodies. Antigens receiving most attention include streptococcal surface proteins that are involved in attachment to tooth surfaces and glucosyltransferases that synthesize adhesive glucans from sucrose. Recent advances in mucosal immunology and the introduction of novel strategies for inducing mucosal immune responses now raise the possibility of constructing an effective and safe vaccine. Passive immunization by the oral application of performed antibodies against selected antigens of mutans streptococci has also shown promise and may facilitate understanding of the mechanisms of protective immunity against caries.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1392004

Source DB:  PubMed          Journal:  Curr Opin Dent        ISSN: 1046-0764


  18 in total

1.  A peptide domain of bovine milk lactoferrin inhibits the interaction between streptococcal surface protein antigen and a salivary agglutinin peptide domain.

Authors:  Takahiko Oho; Floris J Bikker; Arie V Nieuw Amerongen; Jasper Groenink
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Role of serotype-specific polysaccharide in the resistance of Streptococcus mutans to phagocytosis by human polymorphonuclear leukocytes.

Authors:  H Tsuda; Y Yamashita; K Toyoshima; N Yamaguchi; T Oho; Y Nakano; K Nagata; T Koga
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.

Authors:  H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

4.  Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin.

Authors:  G Hajishengallis; S M Michalek; M W Russell
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

5.  Identity of Streptococcus mutans surface protein antigen III and wall-associated protein antigen A.

Authors:  M W Russell; D J Harrington; R R Russell
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

6.  Enhanced immunogenicity of a genetic chimeric protein consisting of two virulence antigens of Streptococcus mutans and protection against infection.

Authors:  Ping Zhang; Christina Jespersgaard; Leticia Lamberty-Mallory; Jannet Katz; Yan Huang; George Hajishengallis; Suzanne M Michalek
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Effects of antibodies against cell surface protein antigen PAc-glucosyltransferase fusion proteins on glucan synthesis and cell adhesion of Streptococcus mutans.

Authors:  H Yu; Y Nakano; Y Yamashita; T Oho; T Koga
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A of Streptococcus sobrinus: persistence and induction of humoral responses in rats.

Authors:  T K Redman; C C Harmon; S M Michalek
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin.

Authors:  J Katz; C C Harmon; G P Buckner; G J Richardson; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A of Streptococcus sobrinus: dose response and induction of protective humoral responses in rats.

Authors:  T K Redman; C C Harmon; R L Lallone; S M Michalek
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.